Is China A Black Swan For Big Pharma? (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Spend a week in Shanghai these days and you hear a lot about how the Big Pharma model is broken. China's life sciences leaders - many of whom are returnees from the U.S. - are talking about this openly, much like industry leaders now do in the U.S. The difference is that many executives on the ground here believe that China is evolving into a laboratory for doing things differently, a catalyst for disruptive innovation that may propel the pharma industry into changing how it develops and delivers drugs